Expert Interview
Investigating the topline results from the Phase 3 ASPEN clinical trial of Brensocatib in patients with bronchiectasis.
Ticker(s): INSMInstitution: Stanford
- Medical Director, Stanford Medical Center Respiratory Care Services where he specializes in both critical care medicine and pulmonary medicine.
- Directs the NTM clinical program at Stanford which manages 200 patients, vast majority have MAC infections.
- Site PI for both the INS-212 and INS-312 trials; clinical focus on the treatment of chronic bronchiectasis and mycobacterial lung infections, and also on rare lung diseases, including lymphangioleiomyomatosis (LAM).
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
